EC Ophthalmology

Introduction: The degree of corneal opacity as an indicator of the effectiveness of the treatment of corneal ulcers.

Inflammatory eye diseases remain a serious problem in practical ophthalmology, as a cause of disability (80%) and as a cause of blindness (10 - 20%). The problem of treatment and rehabilitation of patients with corneal ulcers remains very relevant and far from being resolved in modern ophthalmology.

Purpose of the Study: To assess the degree of corneal opacity using a combined method for the treatment of corneal ulcers.

Methodology: The study included 129 patients (129 eyes) with corneal ulcers. The first group of patients (43 patients in each group) received traditional treatment. In the second group of patients, intrastromal administration of an antibiotic into the cornea was added to the traditional treatment. The third group of patients received complex treatment with the addition of platelet-rich plasma instillations.

Result: The results of the study showed that the use of platelet-rich plasma in combination with intrastromal administration of an antibiotic makes it possible to increase the effectiveness of the treatment of corneal ulcers by reducing the risk of formation of coarse and moderately intense opacities, increases the number of patients with transparent cornea at discharge by 48.8 ± 7.6% of cases (p < 0.05), and in the long-term period - in 76.7 ± 6.4% of cases (p < 0.05).

Keywords: Platelet-Rich Plasma; Intrastromal Administration of an Antibiotic; Corneal Ulcer; Corneal Opacity

1. Wong T. “Severe infective keratitis leading to hospital admission in New Zealand”. British Journal of Ophthalmology 87 (2003): 1103-1108.
2. Livingstone I., et al. “New insight into non-healing corneal ulcers: iatrogenic crystals”. Eye6 (2013): 755-762.
3. Shaimova VA. “Bacterial keratitis. Clinical and immunological features of the course, prognosis, treatment of early forms of the disease: abstract”. Dissertation Doctor of Medical Sciences (2007): 42.
4. Butler TKH. “Infective keratitis in older patients: a 4 year review, 1998-2002”. British Journal of Ophthalmology 89 (2005): 591-596.
5. Green MD. “Clinical outcomes of keratitis”. Clinical and Experimental Ophthalmology 35 (2007): 421-426.
6. Kostyukovich NN. “The discoverer of growth factors and Nobel laureate Stanley Cohen”. Bulletin of the Foundation for Fundamental Research 4 (2011): 112-144.
7. Arshdeep K and Kumaran M. “Platelet-rich plasma in dermatology: Boon or a bane?” Indian Journal of Dermatology, Venereology and Leprology 80 (2014): 5-14.
8. Akhmerov R., et al. “Plasmolifting - Treatment of age-related skin atrophy with platelet-rich autoplasma”. Aesthetic Medicine 2 (2011): 181-187.
9. Achkasov EE., et al. “Application of platelet-rich autoplasma in clinical practice”. Biomedicine 4 (2013): 46-59.
10. Dragonas P., et al. “Effects of leukocyte-platelet-rich fibrin (LPRF) in different intraoral bone grafting procedures: a systematic review”. International Journal of Oral and Maxillofacial Surgery2 (2019): 250-262.
11. Soldatova L., et al. “Role of Leukocyte-Platelet-Rich Fibrin in Endoscopic Endonasal Skull Base Surgery Defect Reconstruction”. Journal of Neurological Surgery Part B: Skull Base1 (2017): 59-62.
12. Geerling G., et al. “Autologous serum eye drops for ocular surface disorders”. British Journal of Ophthalmology 88 (2004): 1467-1474.
13. Kontorshchikova KN., et al. “Determination of platelet growth factors in platelet-rich plasma”. Medical Almanac53 (2018): 41-44.